Yervoy Fails to Shut Down Prostate Cancer but Could Be Effective in a Combo Therapy

Yervoy Fails to Shut Down Prostate Cancer but Could Be Effective in a Combo Therapy
Although the anti-CTLA-4 agent Yervoy (ipilimumab) opens the door to more anti-tumor T-cells entering a prostate-cancer tumor, the treatment produces little patient benefit, a clinical trial indicates. Yerboy activates the immune system by going after the CTLA-4 protein receptor that slows immune-system activity. But prostate cancer responds to Yerboy by increasing the expression of two other immune checkpoint

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *